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MD Anderson
From Lab to Clinic:

Molecular Research Leads to
Clinical Trials for Bladder Cancer

by Sunita Patterson

Above left, Urology fellow Paul Perrotte, M.D., urologist Colin Dinney, M.D., and research assistant Beryl Eve
(left to right) examine a northern blot as part of their study of epidermal growth factor receptor expression. Above right,
Urologist Barton Grossman, M.D., discusses care with a patient in the Genitourinary/Urology Multidisciplinary Care Center.

ile urologists Barton
Grossman, M.D., and Colin
Dinney, M.D., are at work
in the laboratory, they do
not forget the patients they
have seen and operated on that week.
'The ultimate goal of our basic research is to help
patients with disease," said Dr. Grossman, professor
and director of clinical research of the Department of

Urology at The University of Texas M. D. Anderson
Cancer Center. 'We're trying to translate our data
from the laboratory to the clinical arena." Dr. Dinney
is an associate professor in the same department.
In bladder cancer study, years of genetic analysis
and investigation of molecular biomarkers have yielded
results now ripe for clinical trials. These and other
physician-researchers are ready to exploit the increased
understanding of bladder cancer at the molecular level
to predict patient outcome, develop new therapeutic
(Continued on page 2)
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Bladder Cancer Oinical
Trial Interventions
Span Surgery,
Chemotherapy,
Radiotherapy, and
Genetic Manipulation
Bladder cancer clinical trials currently
in progress at The University of Texas
M. D. Anderson Cancer Center include
the following. Contact the M. D. Anderson
Information Line or the M. D. Anderson
clinical trials listing on the World Wide
Web (see numbers and addresses below)
for more information.
• A study of intravesical treatment of
superficial bladder cancer in high- and
low-risk patients characterized on the
basis of tumor markers p53 and pRb.
Physician: Colin Dinney, M.D.
In this trial, Associate Professor Colin
Dinney, M.D., and Barton Grossman,
M.D., both of the Department of

Urology, are investigating the effectiven~ss of the new drug AD 32 against
bladder cancer. After undergoing
surgery to remove bladder tumors,
patients will have their bladders infused
through the urinary tract with AD 32.
After 90 minutes, AD 32 will be drained.
Patients with a low level of protein p53
and pRb expression will receive an
infusion of bacillus Calmette-Guerin
(BCG) into the bladder once a week for
six weeks. Patients with a high level of
protein expression will also receive a
BCG infusion once a week for six weeks.
Both three and six months after the first
infusion, they will receive one BCG
infusion a week for three weeks. This
three-week course will be repeated
every six months for two years.
• Randomized chemoprevention trial
with 4-HPR (fenretinide) in superficial
bladder cancer (95-236). Physician:
Barton Grossman, M.D.
In this trial, Dr. Grossman is investigating the effectiveness of the antitumor
drug 4-HPR (fenretinide) against

superficial bladder cancer's repetitive
recurrence. His aim is to stablize the
urothelium. Patients will take either four
4-HPR capsules a day or four placebo
capsules a day for one year.
• A phase I trial of intravesical adenoviral
p53 treatment in locally advanced
bladder cancer (DM96-1 72). Physician:
Lance C. Pagliaro, M. D.
Assistant Professor of Medicine Lance
C. Pagliaro, M.D., of the Department of
Genitourinary Medical Oncology is
studying gene the rapy fo r bladder
cancer. Adenoviruses carrying the p53
gene will be mixed with a salt water
solution and then infused into the
bladder through the urinary tract. The
solution will be drained after 20 minutes.
Patients will receive two, four, or eight
treatments per month .
• Phase II evaluation of bladder preservation in TO, TA, TIS, and T1 bladder
cancer after chemotherapy (URL96005). Physician: Colin Dinney, M.D.
In this trial, Department of Urology
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From Lab to Clinic
(Continued from page 1)

strategies, and monitor results of
therapy.
In recent work, Drs. Grossman
and Dinney found that expression of
tumor suppressor prote-ins-p-5-S and
Rb, which are known to have an
important role in cell proliferation
and to be altered in many cancers,
correlated with rates of tumor
progression and patient survival in
bladder cancer. After two years, no
patients in whom both proteins were
expressed normally had disease that
metastasized or even invaded muscle;
however, patients in whom both
proteins were expressed abnormally
· had a high rate of progression
(46%), and patients in whom just
one of the proteins was expressed
abnormally had an intermediate
rate of progression (23%). William
Benedict, M.D., of the Department
2 / MD Anderson OncoLog

of Molecular Hematology and
Therapy collaborated with them
on this work.
Using these findings, Dr. Dinney
plans to begin enrolling patients with
recurrent superficial bladder cancer
in a clinical trial this summer. After
resection of their tumors and treatment-with-v-alrubicin- (A9 32-),
patients with normal p53 and Rb
expression will be observed with
cystoscopy only, whereas those with
abnormal expression of one or both
proteins will undergo additional
therapy with bacillus CalmetteGuerin. The goals of the trial are
to determine whether progression
rates at 12 and 24 months are indeed
low in patients with normal p53
and Rb and to study the safety and
efficacy of valrubicin in combating
recurrence and progression.
"These proteins are helping us
to individualize therapy based on
the biologic status of the neoplasm
rather than putting all patients with

superficial bladder cancer in the
same basket," Dr. Grossman said.
Many of these patients will have
recurrences, but in only a few will
disease become invasive or lifethreatening.
Molecular intervention is another
therapeutic strategy. Reports that
altered expressi0n of-p-§3 w-as-asseE-i~
ated with poorer prognosis prompted
researchers to test whether restoring
p53 expression by inserting an
adenoviral vector could induce
disease regression in patients with
locally advanced or metastatic
bladder cancer. "This approach has
had encouraging results so far in
clinical trials at M. D. Anderson in
lung and head and neck cancer," said
study chairman Lance Pagliaro, M.D.,
of the Department of Genitourinary
Medical Oncology.
The preliminary trial in bladder
cancer should determine whether
intravesical administration of the
adenoviral vector is safe and effec-
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Associate Professor Colin Dinney, M.D.,
will treat patients who have superficial
bladder cancer that is invasive or
metastatic that has demonstrated a
dramatic response to chemotherapy.,
They will receive injections of a culture of
live BCG once a week for six weeks after
excision of their tumors. Three months
later, the injections will be given once a
week for three weeks. This three-week
course will be repeated after another
three-month pause and then every six
months for three years. Patients who
have no evidence of disease after
chemotherapy will undergo a physical
exam and tests every three months for
three years. These patients will not
receive BCG unless disease recurs.
• A phase II prospective trial of accelerated concomitant boost radiotherapy in
transitio nal cell carcinoma of the bladder
(I095-212). Physician: Alan Pollack,
M.D., Ph.D.
Associate Professor of Radiation
Oncology Alan Pollack, M.D., Ph.D., of
the Department of Radiation Oncology
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tive. "If the p53 gene is incorporated
and expressed by the bladder tumor
cells, there may be a benefit to
patients," Dr. Pagliaro said. Patient
recruitment was expected to begin
this month.
Another strategy employs chemoprevention to combat frequently
~ recHrring-supeF-ficial bladder cancer
by returning the u rothelium to a
stable state. Dr. Grossman will try to
halt the pattern of recurrence by
using 4-HPR (fenretinide ), an agent
that has shown an titumor activity in
in vitro and animal studies. After
resection, patients whose papillary
bladder tumors have been diagnosed
for the first time or patients who have
had a recurrence more than a year
after initial treatment will be randomized to receive either 4-HPR
or a placebo for 12 months.
In the 4-HPR study, physicians also
will examine a h ost of biomarkers to
determine wh e ther they can serve as
intermediate endpoints, indicating

is studying the effectiveness of radiation
therapy alone for locally advanced
transitional cell carcinoma of the
bladder. Patients will undergo radiation
therapy once a day every weekday for
three weeks. They will then undergo
radiation therapy twice a day every
weekday for two and one-half weeks.
• A phase II trial of taxol, methotrexate,
and cisplatin as neoadjuvant therapy for
advanced bladder cancer (!095-198).
Physician: Randall E. Millikan, M.D., Ph.D.
Assistant Professor of Medicine
Randall E. Millikan, M.D., Ph.D., of the
Department of Genitourinary Medical
Oncology is investigating the combination of paclitaxel (taxol), methotrexate,
and cisplatin against bladder cancers
that are not cured by excision of the
bladder alone. The drugs will be given
by long-line infusion over five hours.
The infusion will be given 10 times
(days 1 and 8 in five 21-day cycles).
• Phase II surgical consolidation for
subdiaphragmatic retroperitoneal

treatment effect earlier than the
standard endpoint of tumor recurrence or progression. Alteration of
biomarkers may precede clinical
evidence of disease by months or
years. Conversely, normalization of
biomarkers may indicate regression
or eradication of disease.
"We-a-re seeing tc-hat biom-arkers
do provide clinically relevant information," Dr. Grossman said. "The
question is, how do we incorporate
them into our practice?"
One answer is a biomarker laboratory project Dr. Dinney hopes to
bring into the clinic within the next
year. With Robert Radinsky, Ph.D.,
of the Department of Cell Biology,
Dr. Dinney has been studying the
effects of inactivating the epidermal
growth factor receptor (EGFR) ,
whose levels are elevated in 50% of
bladder cancers. EGFR overexpression
is associated with increased tumor
size and grade and decreased patient
survival rates.

and pelvic lymph node metastases
following response to chemotherapy in
patients with transitional cell carcinoma
of the bladder and node-only disease
(I096-193). Physician: Louis L. Piste rs,
M.D.
Assistant Professor of Urology
Louis L. Pisters, M.D., of the Department of Urology is studying the effects
of excision of the bladder and retroperitoneal and pelvic lymph nodes in
patients who have received chemotherapy for transitional cell carcinoma.
Patients with subdiaphragmatic
nodal metastasis from transitional
cell carcinoma with or without the
bladder present are study candidates.
FoR MORE INFORMATION about these clinical
trials, physicians or patients should call
the M. D. Anderson Information Line.
Those in the United States, call ( 800)
3 92-1611; those in Houston or outside
the United States, call (713) 792-6161 .
Visit the M. D. Anderson Cancer Center
clinical trials Web site at http:/I
www.clinicaltrials.org.

Dr. Dinney has used several
strategies to inactivate the EGFR in
bladder cancer cell lines and a nude
mouse model. For example, C225
anti-EGFR antibody produced
remarkable regression of tumors.
In addition to a grossly measurable
effect, he found changes in biomarkers of apoptosis, angiogenesis,
proliferation, and invasion. With
Randall Millikan, M.D. , of the
Department of Genitourinary Medical Oncology, Dr. Dinney is designing
a clinical trial that combines antiEGFR therapy with chemotherapy.
"An important aspect of the trial
will be evaluating clinically some of
the cellular proliferation, invasion,
and metastasis biomarkers from our
preclinical studies," Dinney said. •
FoR MORE INFORMATION, contact Dr.
Grossman or Dr. Dinney at (713)
792-3250, or call the M. D. Anderson
Information Line at (800) 392-1611
or (713) 792-6161.
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What Happens
to Me Now,
Doctor?

Practice Guidelines
and Collaborative Paths
Point the Way
by Sunni Hosemann
eople diagnosed with
cancer want answers.
They want reassurance.
They want their physician
to answer the question, "vVhat happens
to me now, doctor?"
For these patients as well as the
health care professionals who serve
them, answering the question of what
happens next in a cancer diagnostic
workup and treatment plan has been
made more clear-cut by the creation
of clinical guidelines and collaborative care paths, disease management
tools essential in the age of managed
care and limited resources. Each has
specific uses, and each offers information that can reassure patients
about wh at will h appen next.
At The University of Texas M. D.
Anderson Cancer Center, practice
guidelines are created as clinical
algorithms for specific disease
processes. Each represents a broad
overview of the disease process and
the approaches to multidisciplinary
medical care that encompass addressing the entire clinical spectrum: for
example, diagnosis, initial evaluation,
staging, further diagnostic workup,
initial treatment, response assessment, adjuvant treatment, surveillance, and salvage (with rehabilitation and follow-up) or palliation.
Crafted by multidisciplinary teams
of physicians, nurses, and others,
each practice guideline sets out an
evidence-based multidisciplinary
medical model of care that incorpo-

P
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rates up-to-date best practices and
reports from the medical literature.
The guidelines aggregate what is
currently known and present it in
a usable format.
Collaborative care paths, more
specific plans that define treatment
and expected outcomes, are developed for on-the-scene clinical practice. These critical paths or care maps
outline the expected or optimal
sequence and timing of interventions
for a specific procedure or course of
treatment, and for a specific disease.
For ovarian cancer, for example,
there is a path for patients on
carboplatin outpatient chemotherapy
and another for patients on taxolcarboplatin chemotherapy. Paths
at M. D. Anderson incorporate a
compreh ensive package for managing patient care: a timeline of expected outcomes, nursing documentation guidelines, standard (but
flexible) sets of physician orders,
consent forms, and patient education
materials. Outcomes and variances
from paths are tracked, and as new
d ata accumulate, the path may
change to ensure the best care. In
this way, the path remains dynamic.
Mapping paths and guidelines
in health care has been stimulated
by the growth of managed care and
efforts to use resources more efficiently, and their use at M. D. Anderson has decreased cost and variability
of treatment, according to Mitchell
Morris, M .D. , vice president for
information services and health care
systems, who oversees guideline and

path development. In fact, in an early
cost comparison of p a tient care (30
patients enrolled on a p ath and 73
others treated before d iscussions of
paths began) , total costs fell 20% ,
and laboratory test costs dropped
74%. No patients on the path reported in a patient satisfaction survey
that they believed they had been
discharged too soon, an d about 85 %
agreed or strongly agreed that the
physicians were caring. Dr. Morris
argues that the value of the paths
goes beyond cost cutting, though
length of stay and costs have seen
significant reductions.
"It's about quality," he said. The
goal is not to shorten length of patient
stay, according to Dr. Morris, but to
determine what the appropriate length
of stay is-in essence, to determine
how to provide the highest quality of
care for every patient. Paths, then,
become a foundation on which to

The director of the
Thoracic Multidiscipinary
Care Center, athoracic
surgeon, and a radiotherapist worked as the
core team preparing this
guideline for non-small
cell lung cancer.
Abbreviations:
PE, physical examination;
CXR, chest X-ray; CT,
computed tomog raphy;
CBC, complete blood cou nt,
Pits, platelets; Na, sodium;
K, potassium; Gluc, glucose;
Creat, creatinine; T Bili,
bilirubin; Alk Phos, alkaline
phosphatase; LOH, lactate
dehydrogenase; SGPT,
serum glutamate pyruvate
transaminase; Ca, calcium;
EKG, electrocardiogram;
PFT's, pulmonary function
tests; prn, pro re nata (as
needed); MRI, magnetic
resonanceimaging; Wt,
weight; chemo, chemotherapy; XRT, X-ray therapy;
post-op, postoperative;
met, metastasis.
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Non-Small
DIAGNOSIS

I

Path review
History+ P~
Physical; C~
CT chest/UPI
abdomen
CBC, Pits, Nj
K, Gluc, Cre;
T Bili, Alk Pf
LDH, SGP
EKG if hist
heart disea

*PFT's: Spirometry +/broncho·dilators and prn
xenon; prn excercise oxygen
consumption testing
**Complete staging workup
with bone scan and CT brain
if symptoms present or eleva
alk phos.

build care, a way to eliminate unnecessary or ineffective procedures, and
to determine and document where
variations from optimal care occur.
By tracking the outcomes and variances from the path, physicians and
nurses can revise plans and raise
treatment quality.
"You don't know where you are
until you look at the data," said
Loretta Murphy, RN., M.B.A. , O.C.N,
associate administrator in the Practice Outcomes Program , a part of Dr.
Morris's guidelines an d paths development team. "These are tools that
will enable us to truly practice
evidence-based medicine," she said.
"The fact that we're tracking
outcomes is also important to patients, " sh e added. "T hey want to see
that they're in the best situation."
Dr. Morris is enthusiastic about
specific features of M. D. Anderson's
paths:

■ They are physician driven, both

in development and application.
Advanced practice nurses are teammates. Dr. Morris and his group
designed the process this way because, he said, 'We [physicians and
nurses] are the ones who should be
defining care-not actuaries or
insurance companies."
A team develops a guideline or·
care path, and then it is reviewed by
all physicians who treat that type of
cancer. After approval, the finished
product is placed in a standard
format for distribution and use.
■ The paths are patient focused.
At M. D. Anderson, more than 500
patients are currently on paths each
month, and patient satisfaction is a
major tracking point.
■ The paths are enhanced with
information for patients. Patient
education materials are embedded
in the paths and accessible through

the same computer application
program as the paths. The materials
can be downloaded in some clinics;
others obtain them from the Office
of Patient Education. The education
office has worked closely with the
Practice Outcomes Program to
develop materials that parallel the
paths and present what Director of
Patient Education Louise Villejo
calls "a story" of their care. This
story is a road map for the patient.
"Most cancer patients are thirsty for
knowledge," Murphy said. "It's often
the only sense of control they have
over this complex and potentially
· devastating disease."
Seventeen cancer guidelines
are complete and available on the
institution's Cancer Manager Program
at http:/ / www.cancermanager.org on
the World Wide Web. Others will be
added as they are completed. •

Cell Lung Cancer

------------------------------------------------~!
INITIAL TREATMENTS

~ Clinical Trial

Operable** ·

Mediastinoscopy

Mediastinoscopy
Positive

,,# _ _optional
Operable**
_ ____.

T1 , T2, NO
(Mediastinal CT
negative - lymph
nodes <1cm)

----~Inoperable ♦@
/
Inoperable

Cervical mediastinoscopy,
Anterior mediastinotomy
(Chamberlain procedure), or
Video Assisted Thoracic
Operable ** ♦ Surgery~

Surveillance

~I.__
To B
or _
C Below
_
___.I

Negative

-----Bronchoscopy with
Surgical Resection
Bronchoscopy with
Surgical Reseciion
Negative ~

Positive

Post-Op XRT or
Clinical Trial

Chemo +/- palliative XRT or
.. ~ ...c_Ii_nic_a_IT_ria_I_ _ __
PosItIve

Induction chemotherapy followed
by chest radiotherapy

B

XRT or Resection in selected cases
followed by Post-Op XRT
se
Resection &
,.__ _ Response ~ Post-Op XRT
Chemo +/- Palliative XRT or Clinical Trial

a,
at,
T4, NO (to include
Pancoast tumor)
Unresectable by
radiological criteria

•

Potentially resectable
by radiological criteria

Mediastinoscopy pos
Performance Status <1=2
and Wt loss <5%

.led
Malignant pleural
effusion or any M1

MD Anderson OncoLog / 5

Prostate Cancer

Patients To Test Exerdse Theory
in Quality-of-Life Study
by Alison Ruffin
"We are targeting several aspects
of quality of life, including feelings
of mental and p hysical well-being in
these patients. This physical activity
program m ay assist in reh abilitating
these men, who often live many years
with prostate cancer," said Bernard
Levin, M.D. , M . D. Anderson's vice
president for cancer prevention.
The study's approach to exercise
is to make physical activity a lifestyle
habit rather than a practice restricted
to a structured exercise regimen.
Dr. Gritz believes a lifestylebased p rogram may be more
"We want to determine
appealing to older patients
and to those who suffer from
whether increased physical
a chronic illness.
adivity can lead to better
"Incorporating moderate
physical activity into their
symptom management and an
daily lives may serve as a
overall feeling of well-being:'
bridge to improved mood
and may be m ore appealing
- Ellen R. Gritz, Ph.D.
than standard psychological
group therapy, used by many
for dealin g with depression,"
said researcher Cindy
Carmack, Ph.D., clinical
psychologist in the Departor those who decline to undertake a strucment of Beh avioral Science.
tured exercise program, incorporating a few
The six-month program
daily physical activities in their schedule is a
includes b ehavioral skills
way of overcoming a sedentary lifestyle. The
training that teaches
increased activity can include integrating several
participants to incorporate
two-minute walks throughout the course of the day.
physical activity into their
A minimum of 30 minutes per day of physical
daily lives. The group sesactivity of at least moderate intensity provides the
sions, which spouses may
opportunity to become more physically fit.
attend, incorporate
discussion of a number
• Get off the bus a block early and walk the rest of
of issues prostate cancer
the way.
patients face, including
• Walk a block or two for lunch instead of going
effects of treatment and
to the restaurant across the street.
changes in sexu ality.
• Take a walk during a television commercial.
The grant was one of
• Park farther away from rather than closer to a
only two awarded nationstore (don't look for the closest spot).
wide on the topic of quality
• Take the stairs instead of the elevator.
of life of p atients with
• Make several trips to bring in groceries.
prostate cancer and one of
• Use a push mower instead of a power or riding
39 recently given to M. D.
mower.
Anderson by the American
• Use a rake instead of a leaf blower.
Cancer Society. •

an exercising "the
easy way " by making a few lifestyle
changes-climbing
stairs rather than taking the
elevator and using a push
lawn mower instead of a
riding mower--improve the
life of patients with prostate
cancer?

C

This is the question
investigators at The University of Texas M. D. Anderson
Cancer Center will examine
in a $685,000 study funded
by the American Cancer
Socie ty.
Proposed by M. D.
Anderson researchers in
response to a request by the
American Cancer Society,
the three-year project will
evaluate what impact
physical activity has on the
quality of life of men with
prostate cancer who were
treated with androgenablation therapy.
"We want to determine
whether a healthy lifestyle
change, namely, increased
physical activity, can lead to
better symptom managem ent and an overall feeling
of well-being in these
patients, in hopes that they
will incorporate these
changes on a permanent
basis," said Ellen R. Gritz,
Ph.D., principal investigator
for the project and chair of
the Department of Behavioral Science.
Androgen-ablation
therapy, used for men
whose prostate cancer has
spread following unsuccess6 / MD Anderson OncoLog

fol initial treatment, seeks to control
prostate cancer cell growth by
eliminating the male sex hormones
on which the cells depend. It may
result in fatigue, muscle weakness,
weight gain or change in weight
distribution, and a decline in bone
mass. Exercise is known to improve
physical fitness and to help reduce
some of these symptoms and, in
addition, reduce levels of stress and
depression, which many cancer
patients experience.

Overcoming a Sedentary
Lifestyle Two Minutes at a Time
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New Survey
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Put your stethoscope to the heart of OncoLog
and tell us what you hear.

Care

------

OncoLog's h eart b eats for you , and we want to know if you hear it. Respond to the questions below.
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your cancer informatio n needs. N ow what do you hear?
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How is ONCOLOG valuable to you?
Check all boxes that apply :
□ Educational
□
0 A partner in improving care
□
0 A partner in interpreting
□
basic science
□

ational Cancer
g questions:
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rd treatment?
ment?
standard

Useful in day-to-day practice
Useful in interaction with patients
Useful in planning treatment
Other

f) Has something you learned in ONCOLOG helped keep you up-to-date?

? Does the
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□

□

□

□

□

□

□

□

C) Do you save issues of ONCOLOG for as long as a year?
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□

0

□

□

0

□

□

Treatment planning
Other
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for your patients?
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M. D. Anderson, about its services, or about its faculty?
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• On the Internet, you prefer graphics to be □ expanded O limited.
• For the ON COLOG , you prefer a version that comes to you by
□ mail □ Internet.
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The New Math of Today's Health Care
Mitchell Morris, M.D.
Vice President for Information
and Health Care Systems
The effects of the
managed care
movement and the
controversy over
financing health
care stimulate a
half dozen news
stories across the
country every day
along with editorial page speculation about health care's future. The
question is basic: how is less more? How
can fewer caregivers, fewer tests, less
medicine, and less time in the hospital
add up to more-higher quality care?
This is the core of the debate for both
physicians and patients. How do both
ensure that quality of care remains high
yet cost is reasonable? Unfortunately,
what too often is left out of the equation
by which we calculate today's care is what
has been added and the nature of what
has been subtracted.
What has been added is health care's
collaborative multidisciplinary response
to demands for more efficient care.
That response, not represented in the
DRG, FTE, and LOS litany, has been
the crafting of practice guidelines and
critical paths meant to guide decision
making across the continuum of care,
from diagnosis through rehabilitation
or palliation.
8 I MD Anderson OncoLog

But before implementation, th
"additions" did not look lik plu
Some physicians understandably £ ar d
violation of the patien t-phy ician
relationship. Others fear d lo of
autonomy. Still other wer war of
changing time-tested practice b cau
of some reengineer's dream of cookiecutter physicians or ome in urer'
desire for a fatter profit margin.
What determines their value i
how they are created. The way to make
viable care paths is not to u evid nee
from claims, but experience from
physicians, nurses, and other in ol ed
intimately with care; not to r 1 on
bottom-line thinking, but to aim for
top-of-the-line caring; not to d mand
patients' outcomes conform to an
artificial standard, but to u quality
outcomes to identify appropriat
measures. As I wrote el ewhere: "Medicine is more complex than cooking
eggs; patients are not alway read to
go home when the timer goe off."
What was subtracted wa unnece sary- not necessary-practice variability, excessive- not essential-laborator
tests, and overextended-not requisite- hospital stays.
What's the sum? With implementation, the paths with their preprinted
orders, multidisciplinary collaborative
care orientation, supporting patient
education materials, and quality
outcomes component have reduced
cost without reducing the quality of
care. obody argues that that is less.
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